Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DRIO vs XBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XBIO Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–4 Matrix Metrics)

XBIO Overall Winner 6-Pillar Tally: DRIO 2 – 2 XBIO (2 Tie) Matrix Metrics: DRIO 4 – 6 XBIO

As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). DRIO carries a Unified Composite Score of 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin), whereas XBIO carries 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin).

  • Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile XBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DRIO vs XBIO
DRIO NASDAQ
DarioHealth Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-8.33% 1D
Market Cap $16.3M
TTM Revenue $21M
Forward P/E 10.6x
Beta / 30D Vol 0.45β · 182% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.0%), weak momentum, RSI 24
RSI-14: 24.0 · SMA20: $2.34 · SMA50: $4.46
XBIO NASDAQ Head-to-Head Winner
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.40
-9.09% 1D
Market Cap $3.6M
TTM Revenue $3.3M
Forward P/E N/M
Beta / 30D Vol 1.40β · 99% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 25.0 Fund 56.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.1%), weak momentum, RSI 30
RSI-14: 29.9 · SMA20: $1.81 · SMA50: $2.14

6-Pillar Scorecard Institutional Category Breakdown (DRIO 2 – 2 XBIO)

Columns: Metric · DRIO · XBIO
1. Valuation Multiples DRIO
Forward P/E 10.6x N/M
Trailing P/E 10.6x N/M
PEG Ratio N/M N/M
EV / Revenue 0.8x 1.1x
2. Growth & Scale DRIO
Revenue Growth (YoY) +6.1% +12.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $21M $3.3M
Market Cap $16.3M $3.6M
3. Profitability & Quality XBIO
Gross Margin 61.3% 100.0%
Operating Margin -142.7% -81.0%
Net Profit Margin -159.9% -75.9%
Return on Equity (ROE) -46.6% -47.0%
4. Balance Sheet & Cash Flow XBIO
Cash Generation (TTM) -$28M EBITDA -$1.8M
Cash Flow Margin -132.8% EBITDA Mgn -55.8%
Net Cash / Leverage $6.37 Book/Sh · -46.6% ROE $3.23 Book/Sh · -47.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DRIO (4) vs XBIO (6)
Institutional Metric DRIO XBIO Criterion Row Edge
Market Capitalization
Scale
$16.3M $3.6M Larger Scale DRIO
Trailing P/E Ratio
Valuation
10.6x N/M Lower Multiple DRIO
Forward P/E Ratio
Valuation
10.6x N/M Lower Multiple DRIO
Revenue Growth (YoY)
Growth
+6.1% +12.0% Higher Growth XBIO
Operating Margin (TTM)
Profitability
-142.7% -81.0% Higher Margin XBIO
Net Profit Margin
Profitability
-159.9% -75.9% Higher Margin XBIO
Return on Equity (ROE)
Capital Efficiency
-46.6% -47.0% Higher ROE DRIO
52-Week Range Position
Momentum
2% ($1–$15) 4% ($1–$5) Stronger Trend XBIO
Beta / 30D Volatility
Risk Regime
0.45β · 182% Vol 1.40β · 99% Vol Lower Realized Risk XBIO
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite XBIO
Trailing 12M Revenue (USD)
Operating Scale
$21M $3.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.3% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M EBITDA ($6.37 Book/Sh · -46.6% ROE) -$1.8M ($3.23 Book/Sh · -47.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XBIO +33.83 pp
DRIO: -61.29% · XBIO: -27.46%
3M Horizon XBIO +18.44 pp
DRIO: -81.69% · XBIO: -63.25%
6M Horizon XBIO +29.43 pp
DRIO: -83.21% · XBIO: -53.78%
1Y Horizon XBIO +45.69 pp
DRIO: -90.57% · XBIO: -44.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRIO vs XBIO. Trailing 12-month operating profitability (DRIO -142.7% vs XBIO -81.0%) and valuation multiples (DRIO 10.6x vs XBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DRIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.3%
Op. Margin-142.7%
ROE / Fwd P/E-46.6% · 10.6x
XBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.3M
Gross Margin100.0%
Op. Margin-81.0%
ROE / Fwd P/E-47.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DRIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DRIO Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $16.3M market capitalization and -142.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6M market capitalization and -81.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DRIO vs XBIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). DRIO carries a Unified Composite Score of 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin), whereas XBIO carries 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin). Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile XBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DRIO leads the Growth & Scale pillar: DRIO posts +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin), compared with XBIO at +12.0% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (100.0% gross margin, -81.0% operating margin). On trailing 12-month operating scale, DRIO generates $21M in USD-normalized revenue versus $3.3M for XBIO. In operating R&D and SG&A reinvestment, DRIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XBIO.

DRIO screens cheaper on headline valuation multiples. DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin), whereas XBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-55.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRIO (-46.6% ROE) versus XBIO (-47.0% ROE) capital efficiency.

In options market volatility and institutional positioning, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk). By comparison, XBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 99% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.